

January 26, 2021

Daniel J. Starck
Chief Executive Officer
Apria, Inc.
7353 Company Drive
Indianapolis, Indiana 46237

Re: Apria, Inc.
Registration

Statement on Form S-1

January 25, 2021

Response Dated

File No. 333-252146

Dear Mr. Starck:

We have reviewed your response dated January 25, 2021, and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our January 20, 2021, letter.

Correspondence filed January 25, 2021

Notes to Consolidated Financial Statements
1. Summary of Significant Accounting Policies
Stock-Based Compensation, page F-19

1. You state on page F-19 that the fair value of your profit interest units and SARs are not subsequently remeasured unless the conditions on which the award was granted are modified. Please tell us how your accounting policy for stock-based compensation is consistent with ASC 718, including the basis of classifying the awards as liabilities or equity. Tell us the specific terms of settlement for each type of award.

Daniel J. Starck
FirstName
Apria, Inc. LastNameDaniel J. Starck
Comapany
January 26, NameApria,
2021 Inc.

January
Page 2 26, 2021 Page 2
FirstName LastName

2. You state that the third-party valuation firm utilized both the income approach and the guideline approach. Tell us how you determined the fair value with these two methods. For example, were the two methods combined, and if so, how was the valuation determined.

3. You state on page 138 of your January 15, 2021 amendment that in connection with the 2020 Dividend the strike price of SARs was reduced and in accordance with ASC 718 the changes were accounted for as modifications. You also state that the

fair value of each
award immediately before and after the modifications were compared and
no incremental
stock compensation was recognized. As it appears based on your
anticipated IPO price
that the fair value of your stock has increased significantly since
the last grant in May
2020, please tell us why no incremental stock compensation is required
to be recorded in
the December 2020 modification.

Item 15. Recent Sales of Unregistered Securities, page II-2

4. Please tell us and disclose in the filing the number of shares of
common stock you intend
to issue to the pre-IPO owners of Apria Healthcare Group, the basis
for the accounting
treatment for the shares to be issued, and how you will determine the
fair value of the
shares. In addition, please disclose the number of RSUs that will be
granted to your Chief
Financial Officer upon completion of the IPO, which will vest
immediately, and the
amount of stock compensation that will be recorded. Tell us the fair
value you intend to
use for determining stock compensation.

5. Disclose in the filing the number of profit interest units and SARS
the pre-IPO owners
will receive in connection with the pre-IPO reorganization
transactions. Tell us how you
determined the number of profit interest units and SARS the pre-IPO
owners will
receive and how the exchange ratio of each relates to the anticipated
IPO price. In this
respect, please clarify what you mean by the Preliminary Price Range
assumes that in
connection with the pre-IPO reorganization transactions described the
Registration
Statement, pre-IPO owners of Apria Holdings LLC profit interest units
will receive shares
of Apria, Inc. and pre-IPO owners of the Apria Healthcare Group SARS
will receive
SARS in Apria Inc..

6. You state on page 14 of your January 15, 2021 filing that you used the
net proceeds from
the December 2020 Incremental Term Loans to fund a \$200.3 million
dividend
payment
to your stockholders and a \$9.7 million distribution to SARS holders.
Tell us how you
determined the amount of the \$9.7 million distribution to SARS holders
declared and paid
in December 2020 and how the fair value relates to your IPO price. In
addition, disclose
in the filing your anticipated accounting treatment for both the
dividend and distribution to
SARS holders and tell us the basis for the accounting treatment citing
applicable
accounting guidance.

7. Tell us what the fair value per share was for the equity value used
for the grant dates in
October 2019, December 2019, and May 2020.

Daniel J. Starck
Apria, Inc.
January 26, 2021
Page 3

You may contact Jeanne Bennett at (202) 551-3606 or Mary Mast at (202)
551-3613 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Abby Adams at (202) 551-6902 or Laura Crotty at (202) 551-7614 with any
other
questions.

FirstName LastNameDaniel J. Starck
Corporation Finance
Comapany NameApria, Inc.

Sincerely,
Division of
Office of Life

Sciences

January 26, 2021 Page 3

cc: Edgar Lewandowski, Esq.

FirstName LastName